REBECCA KING: Open Payments
NPI 1407500945 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$164 in 8 payments from 6 companies in 2025. Trend: 2023 $20 · 2024 $0 · 2025 $164
Food & beverage: $164
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $43 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Gilead Sciences, Inc. | 1 | $19 |
| Novo Nordisk Inc | 1 | $17 |
Products named: REZDIFFRA, IQIRVO, CAPLYTA, XIFAXAN, Wegovy.
Industry payments across KS — which companies pay providers there.
